Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
ConditionCandida
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Toulouse
About this trial
The aim of this study is to evaluate the implementation of a new technique for invasive candidiasis diagnosis by PCR. The main objective will be to evaluate the effect of this strategy on the time required to obtain results in patients from intensive care units with suspected systemic invasive candidiasis. This PCR method could allow an antifungal switch to be made earlier, limiting the appearance of resistance and reducing the cost of antifungals for healthcare facilities.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient affiliated or benefiting from a social protection system
Patient (or his/her trusted person) having given free and informed written consent to the investigating physician
Non-neutropenic patient hospitalised in the Toulouse University Hospital intensive care unit.
Patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented.
Disqualifiers
Patients under guardianship or trusteeship, persons under court protection
Pregnant or breastfeeding patients.
Trial design
Design model
Parallel
Treatments tested in this trial
Diagnosis strategy based on C. glabrata / krusei PCR
Diagnostic testFor diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
Treatment groups
120 Participants
are divided into 2 treatment groupsGroup A: blood culture-based diagnostic strategyNo intervention 0 interventions
Group B: C. glabrata / krusei PCR diagnostic strategyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Reporting delay
the time (in hours) required for the results to be returned in relation to the time of sample collection
Time frame
14 days after blood sample takenSecondary outcomes
1
mortality at Day 28
Mortality rates will be taken 28 days after taking blood samples for Candida diagnosis in both groups
Time frame
28 days after blood sample takenSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov